Abstract
BackgroundLenvatinib plus PD-1 inhibitors and interventional (LPI) therapy have demonstrated promising treatment effects in unresectable hepatocellular carcinoma (HCC). However, biomarkers for predicting the response to LPI therapy remain to be...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have